2023
Percutaneous Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Pain and Ambulatory Function in Periacetabular Osteolytic Malignancies.
Dussik C, Toombs C, Alder K, Yu K, Berson E, Ibe I, Li F, Lindskog D, Friedlaender G, Latich I, Lee F. Percutaneous Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Pain and Ambulatory Function in Periacetabular Osteolytic Malignancies. Radiology 2023, 307: e221401. PMID: 36916888, DOI: 10.1148/radiol.221401.Peer-Reviewed Original ResearchMeSH KeywordsAgedCatheter AblationFemaleHumansMaleNeoplasmsOsteotomyQuality of LifeRetrospective StudiesTreatment OutcomeConceptsOsteolytic neoplasmAmbulatory functionInternal fixationEastern Cooperative Oncology Group scoreIndex scoreConversion hip arthroplastyRetrospective observational studySurgical site infectionKaplan-Meier analysisLong-term painQuality of lifeLong-term improvementWilcoxon signed-rank testNonambulatory patientsSecondary outcomesPrimary outcomeSite infectionOncologic careECOG scorePercutaneous ablationPeriacetabular metastasisProtrusio acetabuliFunctional improvementSigned-rank testClinical data
2022
Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity
Samuels S, Hu P, Maciejewski K, Li F, Dziura J, Savoye M, Sharifi M. Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity. Obesity 2022, 31: 203-213. PMID: 36502287, PMCID: PMC9780185, DOI: 10.1002/oby.23627.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlack PeopleBody Mass IndexChildFemaleHumansMaleObesity, MorbidPediatric ObesityTreatment OutcomeConceptsPediatric weight management interventionsHealthy lifestyle interventionReal-world effectivenessWeight management interventionsLifestyle interventionChildhood obesityClinical effectivenessFemale sexInsurance categoriesBMIp95Mixed-effects modelsGreater reductionBMIBright bodiesInterventionSexParticipantsManagement interventionsObesityReal-world adaptationYearsTrials
2021
Blood Pressure Trajectory Groups and Outcome After Endovascular Thrombectomy: A Multicenter Study
Petersen NH, Kodali S, Meng C, Li F, Nguyen CK, Peshwe KU, Strander S, Silverman A, Kimmel A, Wang A, Anadani M, Almallouhi E, Spiotta AM, Kim JT, Giles JA, Keyrouz SG, Farooqui M, Zevallos C, Maier IL, Psychogios MN, Liman J, Riou-Comte N, Richard S, Gory B, Wolfe S, Brown PA, Fargen KM, Mistry EA, Fakhri H, Mistry AM, Wong KH, de Havenon A, Nascimento FA, Kan P, Matouk C, Ortega-Gutiérrez S, Sheth KN. Blood Pressure Trajectory Groups and Outcome After Endovascular Thrombectomy: A Multicenter Study. Stroke 2021, 53: 1216-1225. PMID: 34781705, PMCID: PMC8960326, DOI: 10.1161/strokeaha.121.034408.Peer-Reviewed Original ResearchConceptsSymptomatic intracranial hemorrhageEndovascular thrombectomyBlood pressure trajectoriesFunctional outcomeHemorrhagic transformationIschemic strokeSBP trajectoriesIntracranial hemorrhageAnterior circulation large vessel occlusion ischemic strokeModified Rankin Scale (mRS) 90 daysTrajectory groupsLarge vessel occlusion ischemic strokeMulticenter retrospective cohort studySystolic blood pressure trajectoriesBlood pressure courseOptimal hemodynamic managementSBP trajectory groupsRetrospective cohort studyAcute ischemic strokeElevated blood pressurePoor functional outcomePressure trajectoriesBlood pressure dataCohort studySecondary outcomesEarly but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere diseaseImplantable Cardioverter Defibrillator Lead Survival in Athletic Patients
Link MS, Sullivan RM, Olshansky B, Cannom D, Berul CI, Hauser RG, Heidbuchel H, Jordaens L, Krahn AD, Morgan J, Patton KK, Saarel EV, Wilkoff BL, Li F, Dziura J, Brandt C, Barth C, Lampert R. Implantable Cardioverter Defibrillator Lead Survival in Athletic Patients. Circulation Arrhythmia And Electrophysiology 2021, 14: e009344. PMID: 33724879, DOI: 10.1161/circep.120.009344.Peer-Reviewed Original Research
2020
Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer
Usiskin I, Li F, Irwin ML, Cartmel B, Sanft T. Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer. Breast Cancer Research And Treatment 2020, 186: 191-197. PMID: 33125620, DOI: 10.1007/s10549-020-05994-8.Peer-Reviewed Original ResearchConceptsRelative dose intensityPathologic complete responseNeoadjuvant chemotherapyBreast cancerDose reductionDose intensityComplete responseLower BMIHigh relative dose intensityDose delaysTreatment tolerabilityPatient adherenceTreatment delayTumor characteristicsCancer HospitalChemotherapy dosesHigher BMIRetrospective studyResultsOur cohortMedical recordsPurposePrevious workChi-square analysisBMICommon reasonAverage ageRevascularization Options for Females With Multivessel Coronary Artery Disease A Meta-Analysis of Randomized Controlled Trials
Gul B, Shah T, Head SJ, Chieffo A, Hu X, Li F, Brackett A, Gesick C, Bisarya PK, Lansky A. Revascularization Options for Females With Multivessel Coronary Artery Disease A Meta-Analysis of Randomized Controlled Trials. JACC Cardiovascular Interventions 2020, 13: 1009-1010. PMID: 32113933, DOI: 10.1016/j.jcin.2019.12.036.Peer-Reviewed Original ResearchAccess and Outcomes Among Hypertrophic Cardiomyopathy Patients in a Large Integrated Health System
Thomas A, Papoutsidakis N, Spatz E, Testani J, Soucier R, Chou J, Ahmad T, Darr U, Hu X, Li F, Chen ME, Bellumkonda L, Sumathipala A, Jacoby D. Access and Outcomes Among Hypertrophic Cardiomyopathy Patients in a Large Integrated Health System. Journal Of The American Heart Association 2020, 9: e014095. PMID: 31973610, PMCID: PMC7033886, DOI: 10.1161/jaha.119.014095.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCardiomyopathy, HypertrophicCause of DeathConnecticutDelivery of Health Care, IntegratedFemaleHealthcare DisparitiesHeart Disease Risk FactorsHospitalizationHumansMaleMiddle AgedOutcome and Process Assessment, Health CareReferral and ConsultationRetrospective StudiesRisk AssessmentSocial ClassSocial Determinants of HealthTreatment OutcomeConceptsSpecialty careHCM patientsCare cohortHypertrophic cardiomyopathyYale New Haven Health SystemLarge integrated health systemHealth systemBackground Hypertrophic cardiomyopathyRetrospective cohort studySocioeconomic statusPatients' socioeconomic statusHigher socioeconomic status groupsHypertrophic cardiomyopathy patientsIntegrated health systemSpecialty care accessSocioeconomic status groupsMedical insurance providersCardiomyopathy clinicCause deathLSES patientsCause hospitalizationCause mortalityNoncardiac causesCohort studySecondary outcomes
2019
Resection of Cavity Shave Margins in Stage 0–III Breast Cancer Patients Undergoing Breast Conserving Surgery
Dupont E, Tsangaris T, Garcia-Cantu C, Howard-McNatt M, Chiba A, Berger AC, Levine EA, Gass JS, Gallagher K, Lum SS, Martinez RD, Willis AI, Pandya SV, Brown EA, Fenton A, Mendiola A, Murray M, Solomon NL, Senthil M, Ollila DW, Edmonson D, Lazar M, Namm JP, Li F, Butler M, McGowan NE, Herrera ME, Avitan YP, Yoder B, Walters LL, McPartland T, Chagpar AB. Resection of Cavity Shave Margins in Stage 0–III Breast Cancer Patients Undergoing Breast Conserving Surgery. Annals Of Surgery 2019, 273: 876-881. PMID: 31290763, DOI: 10.1097/sla.0000000000003449.Peer-Reviewed Original ResearchConceptsCavity shave marginsBreast cancer patientsPartial mastectomyPositive marginsRe-excision ratesCancer patientsShave marginsStage 0Standard partial mastectomyMedian patient ageSingle-center studyBreast conserving surgeryPrimary outcome measurePositive margin rateConserving surgeryPatient ageClinicopathologic factorsMargin clearanceMargin rateInclusion criteriaOutcome measuresPatientsResectionPractice settingsMastectomyAssociation between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer
Usiskin I, Li F, Irwin ML, Cartmel B, Sanft T. Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer. Breast Cancer 2019, 26: 719-728. PMID: 31119682, DOI: 10.1007/s12282-019-00974-3.Peer-Reviewed Original ResearchConceptsPathologic complete responseChemotherapy completionComplete responseNeoadjuvant chemotherapyLower BMIResidual diseaseBreast cancerPhysical activityNeoadjuvant breast cancer treatmentRetrospective case-control studyUnconditional logistic regression modelsCompletion of chemotherapyMedical record reviewBreast cancer survivalLower mean BMICase-control studyPhysical activity 1Breast cancer treatmentLogistic regression modelsBreast cancer diagnosisMean BMIPatient characteristicsRecord reviewPurposePhysical activityCancer survival
2018
Lymphedema in ovarian cancer survivors: Assessing diagnostic methods and the effects of physical activity
Iyer NS, Cartmel B, Friedman L, Li F, Zhou Y, Ercolano E, Harrigan M, Gottlieb L, McCorkle R, Schwartz PE, Irwin ML. Lymphedema in ovarian cancer survivors: Assessing diagnostic methods and the effects of physical activity. Cancer 2018, 124: 1929-1937. PMID: 29437202, DOI: 10.1002/cncr.31239.Peer-Reviewed Original ResearchConceptsLower limb lymphedemaOvarian cancer survivorsCancer survivorsSelf-report questionnairesSide effectsSpecialist evaluationCancer treatmentDiagnostic methodsRandomized exercise interventionTrial of exerciseBody mass indexPhysical activity recommendationsEffects of exerciseOvarian cancer treatmentGynecologic cancer treatmentLymphedema prevalenceLymphedema specialistExercise groupExercise interventionDifferent diagnostic methodsMass indexBaseline prevalenceActivity recommendationsOvarian cancerLimb lymphedema
2017
Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients
Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP. Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients. Annals Of Surgery 2017, 265: 39-44. PMID: 27192352, PMCID: PMC5605915, DOI: 10.1097/sla.0000000000001799.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularConnecticutFemaleFollow-Up StudiesHealth ExpendituresHospital CostsHumansMargins of ExcisionMastectomy, SegmentalMiddle AgedProspective StudiesReoperationSingle-Blind MethodTreatment OutcomeConceptsCavity shave marginsStandard partial mastectomyPartial mastectomyRe-excision ratesIndex surgeryInitial surgeryBreast cancerHospital perspectiveLower re-excision ratesDirect hospital costsBreast cancer patientsOperating room timeReoperative surgeryBaseline characteristicsOperative timePositive marginsShave marginsCancer patientsHospital costsStage 0Room timeSurgeryPathology costsPatientsMastectomy
2016
Psychosocial predictors and moderators of weight management programme outcomes in ethnically diverse obese youth
Taylor JH, Xu Y, Li F, Shaw M, Dziura J, Caprio S, Tamborlane WV, Nowicka P, Savoye M. Psychosocial predictors and moderators of weight management programme outcomes in ethnically diverse obese youth. Pediatric Obesity 2016, 12: 453-461. PMID: 27384496, PMCID: PMC5568975, DOI: 10.1111/ijpo.12165.Peer-Reviewed Original ResearchConceptsClinic careObese youthOutpatient clinic careAbnormal glucose toleranceObesity treatment outcomesObesity intervention programFamily functioningLifestyle interventionGlucose toleranceChildhood obesityLifestyle programTreatment outcomesPsychosocial predictorsIdentification of factorsIntervention programsIntervention outcomesOutcomesPoor family functioningTreatment effectsHigh anxietyBaselineCareMonthsInterventionAntiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children
Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clinical Infectious Diseases 2016, 63: 414-422. PMID: 27143666, PMCID: PMC4946019, DOI: 10.1093/cid/ciw291.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrine treatmentLPV/rRecurrent malariaLumefantrine exposureDrug exposureCritical drug-drug interactionsFirst-line antiretroviral therapy regimensArtemisinin-based combination therapyLopinavir/ritonavirAntiretroviral therapy regimensPlasmodium falciparum malariaHuman immunodeficiency virusDay 7 concentrationsMalaria-endemic regionsDrug-drug interactionsAntimalarial exposureAntimalarial componentPharmacokinetic samplingArtemether-lumefantrineFalciparum malariaClinical outcomesDosing regimensTherapy regimensImmunodeficiency virusCombination therapy
2014
Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study
Srihari VH, Tek C, Pollard J, Zimmet S, Keat J, Cahill JD, Kucukgoncu S, Walsh BC, Li F, Gueorguieva R, Levine N, Mesholam-Gately RI, Friedman-Yakoobian M, Seidman LJ, Keshavan MS, McGlashan TH, Woods SW. Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study. BMC Psychiatry 2014, 14: 335. PMID: 25471062, PMCID: PMC4262386, DOI: 10.1186/s12888-014-0335-3.Peer-Reviewed Original ResearchMeSH KeywordsDelivery of Health CareEarly DiagnosisHealth Services Needs and DemandHumansPsychotic DisordersTime FactorsTreatment OutcomeUnited StatesConceptsEarly detectionEarly outcomesGeographic catchmentTIPS studyYounger patientsAppropriate patientsUntreated psychosisPsychosis onsetEffective treatmentCare providersPsychotic symptomsPublic education campaignsPsychotic disordersHelp-seeking behaviorSecondary aimComprehensive interventionPatientsIntervention servicesDUPEducation campaignsOutcomesSocial marketing approachPrimary aimTreatmentFESRandomized Exercise Trial of Aromatase Inhibitor–Induced Arthralgia in Breast Cancer Survivors
Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J. Randomized Exercise Trial of Aromatase Inhibitor–Induced Arthralgia in Breast Cancer Survivors. Journal Of Clinical Oncology 2014, 33: 1104-1111. PMID: 25452437, PMCID: PMC4372849, DOI: 10.1200/jco.2014.57.1547.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsBrief Pain InventoryUsual careAromatase inhibitorsCancer survivorsPain scoresAromatase Inhibitor-Induced ArthralgiaInactive breast cancer survivorsMcMaster Universities Osteoarthritis IndexJoint pain scoresRandomized exercise trialWorst joint painPrimary end pointWOMAC pain scoreImpact of exerciseResistance training sessionAI adherenceOsteoarthritis IndexHand questionnaireJoint painPain severityPain InventoryExercise trialsAerobic exerciseWestern Ontario
2010
Determinants of Individual Variation in Intracellular Accumulation of Anti-HIV Nucleoside Analog Metabolites
Paintsil E, Dutschman GE, Hu R, Grill SP, Wang CJ, Lam W, Li FY, Ghebremichael M, Northrup V, Cheng YC. Determinants of Individual Variation in Intracellular Accumulation of Anti-HIV Nucleoside Analog Metabolites. Antimicrobial Agents And Chemotherapy 2010, 55: 895-903. PMID: 21078952, PMCID: PMC3028801, DOI: 10.1128/aac.01303-10.Peer-Reviewed Original ResearchConceptsNucleoside analoguesPeripheral blood mononuclear cellsAntiretroviral drug discoveryThymidine kinase 1 activityBlood mononuclear cellsConcentrations of AZTMetabolite concentrationsIntracellular concentrationAntiretroviral therapyClinical responseMononuclear cellsHealthy donorsHIV therapyTherapy needTriphosphate metaboliteAZT monophosphateAnalogue metabolitesCellular kinasesCassette (ABC) transport proteinsInverse correlationDemographic characteristicsAZTIntracellular accumulationKinase 1 activityIndividual variation